The KRAS-variant is a recently discovered, inherited genetic marker that has significant implications for women's health. It predicts endometriosis and associated infertility, breast and ovarian cancer, and unique responses to agents used to treat these conditions. MiraKind is a research institute working to discover cancer prevention strategies for individuals with this marker, who make up 6% of the general population and up to 20% of cancer patients. We are raising support for our next study, which will examine medical exposures that influence the behavior of this marker. Please support this critical research to find actionable strategies to prevent cancer.